Erasca, Inc. is a clinical-stage precision oncology company. Co. is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Co. has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. We show 14 historical shares outstanding datapoints in our ERAS shares outstanding history coverage, used to compute ERAS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ERAS market cap history over the course of time is important for investors
interested in comparing ERAS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ERAS versus a peer is one thing; comparing
ERAS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ERAS can fluctuate over the course of history.
With this page we aim to empower investors researching ERAS by allowing them to research the ERAS market cap history. |
Free ERAS Email Alerts:
Video: The Importance of Market Cap
